Overview

* Myomo Q3 2025 revenue up 10% to $10.1 mln, helped by record U.S. and International orthotics and prosthetics (O&P) revenue

* Company reiterates full-year revenue guidance of $40 mln to $42 mln

* Operating expenses decreased sequentially but rose 26% yr/yr due to higher advertising and R&D

Outlook

* Myomo ( MYO ) reiterates full-year revenue guidance of $40 mln to $42 mln

* Company expects cost reduction projects to improve margins by Q3 2026

Result Drivers

* RECORD O&P REVENUE - Co achieved record U.S. and International orthotics and prosthetics (O&P) revenue in Q3, contributing to revenue growth

* MYOCONNECT PROGRAM - New MyoConnect program aims to lower cost per pipeline add and improve pipeline quality through therapist and physician engagement

* PATIENT PIPELINE GROWTH - Patient pipeline grew by 28% yr/yr with 826 new candidates added in Q3

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.09

Q3 Net -$3.70

Income mln

Q3 -$2.70

Adjusted mln

EBITDA

Q3 Gross 63.80%

Margin

Q3 $10 mln

Operatin

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)